Benzinga | Jul 28, 2021 05:13AM EDT

Jefferies Upgrades ResMed to Hold, Raises Price Target to $240

Jefferies analyst Anthony Petrone upgrades ResMed (NYSE:RMD) from Underperform to Hold and raises the price target from $170 to $240.